Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET. The management team will engage in a fireside chat, which will be webcast live. An archived recording will be available post-event on their website. Madrigal focuses on innovative therapeutics for non-alcoholic steatohepatitis (NASH) and leads with resmetirom, currently in Phase 3 studies.

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.

The fireside chat presentation will be webcast live and an archived recording will be available for replay in the Investors & Media section of the Madrigal website after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

 

FAQ

When will Madrigal Pharmaceuticals participate in the Oppenheimer Healthcare Conference?

Madrigal Pharmaceuticals will participate in the Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET.

How can I watch Madrigal Pharmaceuticals' presentation at the conference?

The presentation will be webcast live, and an archived recording will be available on the Madrigal website after the event.

What is the focus of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals focuses on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with significant unmet medical needs.

What is resmetirom and its relevance to Madrigal Pharmaceuticals?

Resmetirom is Madrigal's lead candidate, a once-daily oral medication designed to target the underlying causes of NASH, currently being evaluated in Phase 3 clinical studies.

What are the names of the Phase 3 studies for resmetirom?

The Phase 3 studies for resmetirom are named MAESTRO-NASH and MAESTRO-NAFLD-1.